[Comparison of two nonspecific immune stimuli in antiblastic chemotherapy].
Antiblastic chemotherapy was combined with two aspecific immune stimuli, Levamisole Corynebacterium parvum, in 48 and 55 neoplastic patients respectively. C. parvum was found to be more easy to handle, particularly since Levamisole, albeit compensated by absolute lymphocytosis in many cases. In addition, C. parvum proved more effective in patients with lung and oro-pharyngeal neoplasias, whereas Levamisole appeared to be of greater use in breast cancer. Both stimuli led to improved coenaesthesia and performance status by comparison with a control group. It can thus be asserted that aspecific immunotherapy should have a place in the multidisciplinary approach currently sought.
D000276:Adjuvants, Immunologic; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy; D006801:Humans; D007978:Levamisole / Q000276:immunology / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D010610:Pharyngeal Neoplasms / Q000628:therapy; D011425:Propionibacterium acnes / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007978:Levamisole
Alcune considerazioni comparative sull'uso di due immunostimoili aspecifici in corso di chemioterapia antiblastica.